Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.

Journal

Clinical and experimental rheumatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis

Tous les auteurs :
Saraux A, Benichou J, Guillevin L, Idbrik L, Job-Deslandre C, Sibilia J, Soudant M, Wendling D, Guillemin F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26315585

Résumé

Limited information is available about the characteristics of patients with active inflammatory rheumatic diseases who start TNF-α antagonist therapy. Our objective was to assess TNF-α antagonist prescription patterns in this context in France.

Mots clés

Adolescent, Adult, Aged, Antirheumatic Agents, contraindications, Arthritis, Juvenile, diagnosis, Arthritis, Rheumatoid, diagnosis, Child, Drug Prescriptions, Drug Utilization Review, Female, France, Humans, Immunologic Factors, contraindications, Longitudinal Studies, Male, Middle Aged, Patient Selection, Practice Patterns, Physicians', trends, Prospective Studies, Severity of Illness Index, Spondylarthropathies, diagnosis, Time Factors, Treatment Outcome, Treatment Refusal, Tumor Necrosis Factor-alpha, antagonists & inhibitors, Young Adult

Référence

Clin. Exp. Rheumatol.. ;33(5):602-10